Data / Form D filings / Rezo Therapeutics, Inc.
Rezo Therapeutics, Inc.: Form D filings
Rezo Therapeutics, Inc., a biotechnology company in San Francisco, CA, filed 3 Form D notices with the SEC between 2022 and 2025. The latest, on August 18, 2025, reports $68.1 million sold of a $80.1 million offering to 21 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 455 MISSION BAY BOULEVARD SOUTH, SUITE 525, San Francisco, CA, 94158
- Phone
- (415) 310-4524
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1956559
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Amendment | $80,129,936 | $68,066,039 | $12,063,897 | 21 | Jul 21, 2022 | sec.gov |
| Dec 18, 2023 | Amendment | $80,129,936 | $46,348,088 | $33,781,848 | 20 | Jul 21, 2022 | sec.gov |
| Dec 1, 2022 | New notice | $80,129,936 | $14,616,238 | $65,513,698 | 20 | Jul 21, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Simeon George | Director | |
| Derek Hicks | Executive Officer, Director | |
| Nevan Krogan | Executive Officer, Director | |
| Tiba Aynechi | Director | |
| Jennifer Chang | Executive Officer | |
| George Scangos | Director | |
| Norbert Bischofberger | Director | |
| Vineeta Agarwala | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 18, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Rezo Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.